NR1H4 and prostate cancer: Other pharmaceutical agents have since been FDA-approved for prostate cancer (androgen receptor (AR) antagonists), acute promyelocytic leukemia (retinoic acid receptor (RAR) agonists), AIDS-related Kaposi’s sarcoma (RAR and retinoid X receptor (RXR) agonists), and cutaneous T-cell lymphoma (RXR modulators), while others are currently in clinical trials (ER, AR, RAR, RXR, glucocorticoid receptor (GR), RAR-related orphan receptor (ROR), vitamin D receptor (VDR), peroxisome proliferator-activated receptor (PPAR), liver X receptor (LXR), and farnesoid X receptor (FXR))10.